A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Hoosier Cancer Research Network
University of Southern California
AHS Cancer Control Alberta
University of Pisa
University of Birmingham
University of Miami
Stanford University
Federation Francophone de Cancerologie Digestive
University of Pittsburgh
Abramson Cancer Center at Penn Medicine
Assistance Publique - Hôpitaux de Paris